Cingulate Announces Positive Top-Line Results from Fed/Fast Study of Lead Asset…
<!-- Name:DistributionId Value:8755907 -->
<!-- Name:EnableQuoteCarouselOnPnr Value:False -->…
Browsing Tag
CTx1301
Cingulate Completes Fed/Fast Study Assessing Food Effect with CTx-1301, Lead…
KANSAS CITY, Kan., Nov. 01, 2022 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery…
Cingulate Provides 2022 Clinical Plan for CTx-1301, an Investigational Medication for…
KANSAS CITY, Kan., Feb. 08, 2022 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a clinical-stage biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™)…